{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/scarlet-fever/prescribing-information/azithromycin/","result":{"pageContext":{"chapter":{"id":"ce256942-e7de-5014-bdf7-f34be5755538","slug":"azithromycin","fullItemName":"Azithromycin","depth":2,"htmlHeader":"<!-- begin field fc4764e7-9e0a-49f2-aa93-73a8d35d8872 --><h2>Azithromycin</h2><!-- end field fc4764e7-9e0a-49f2-aa93-73a8d35d8872 -->","summary":"","htmlStringContent":"<!-- begin item d76ffeb2-1f24-4d00-8ea9-7d34ce05dc55 --><!-- end item d76ffeb2-1f24-4d00-8ea9-7d34ce05dc55 -->","topic":{"id":"7c05f7c5-902d-5982-8cc9-5f1d301d214d","topicId":"f534013d-38dd-4f96-bc65-37091262952c","topicName":"Scarlet fever","slug":"scarlet-fever","lastRevised":"Last revised in March 2020","chapters":[{"id":"d3f6c278-a759-50f3-9a96-734913f439ab","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"ffff4a88-7ddf-55dc-a37b-1625f3f58e2b","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"89be33c0-acbe-51fd-901b-d7cf571435a4","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"61377ddb-df7a-50fb-9dd7-224014332a4e","slug":"changes","fullItemName":"Changes"},{"id":"b5e95aca-9003-52f8-b6e7-0c192c5ba757","slug":"update","fullItemName":"Update"}]},{"id":"90d2085f-63f5-57a1-b21e-21d4c580229a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"cc3aa630-ef6b-5504-9439-6a4757e7fe43","slug":"goals","fullItemName":"Goals"},{"id":"ebf64432-58f2-513f-a393-ec4e8438f355","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"b3da9abe-7cc8-5c97-970d-39b1416de8cb","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"8b3309e1-1d9f-520e-b310-592706c0951d","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"0603af50-edd7-5e78-a394-1fd6a1a1af21","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"00da52ed-356a-563d-aa3c-dc4e3ee27155","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"7072120a-72ec-5945-b4f0-e4386374e1ad","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"f61354f7-80ff-5483-89fc-51be1d57b5d3","slug":"definition","fullItemName":"Definition"},{"id":"4dc22989-c1d3-5880-a381-78cabd38ca4d","slug":"transmission","fullItemName":"Transmission"},{"id":"c4e4e4ff-9b93-5d55-8ae0-5e0b1a518ef3","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"5b31f083-75b7-5ae3-9029-87df9bc061cf","slug":"prevalence","fullItemName":"Prevalence"},{"id":"94ffb885-96f6-595f-b1ad-fb146a27db30","slug":"complications","fullItemName":"Complications"},{"id":"f3bf38a0-7946-504a-b22c-654728a0366a","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"ffb84f0d-77eb-5011-a50d-14d9143e4bd4","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"8484304f-9507-5401-8c08-2c93126a8b3f","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"601ddd63-7670-5740-a0f6-fe317e0d7770","slug":"investigations","fullItemName":"Investigations"},{"id":"a1df37ba-9251-52d5-8376-b19803e39cc3","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"5329e2f2-3618-5113-8fc1-5228ff864869","fullItemName":"Management","slug":"management","subChapters":[{"id":"963d805b-33a2-5e78-9195-323379519c7e","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"db4a097c-9d97-5e1e-8718-e082e8e25f5e","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"4a26593a-c9e4-5523-a6d2-5feb274dcf79","slug":"phenoxymethylpenicillin","fullItemName":"Phenoxymethylpenicillin"},{"id":"2a494a84-0688-5337-8f03-a2ab33a654fb","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"ce256942-e7de-5014-bdf7-f34be5755538","slug":"azithromycin","fullItemName":"Azithromycin"}]},{"id":"7e3b4438-f437-5199-8ee5-f3c9d210b732","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"f2446794-c34e-574f-8de3-c5ecbe3c4f35","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"1a90ff7f-b2b6-5959-86a0-3cea6609706f","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0d14df6f-1299-58da-b620-c970e5b90b91","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"db42b54d-b095-52b7-9cb1-37d73c57fdb7","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"551dac2a-e65d-57c4-b16c-279891510a2b","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"5d76e530-4218-5600-a9ed-896a3245aefb","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"03221ed8-00f7-5819-b90c-cc69c4a1fdb8","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"db4a097c-9d97-5e1e-8718-e082e8e25f5e","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"066fa184-9fe9-575c-af7b-bff20cd3415a","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 0e9e0958-ccc1-4ee3-b0ee-a74400cd7b4c --><h3>Contraindications and cautions</h3><!-- end field 0e9e0958-ccc1-4ee3-b0ee-a74400cd7b4c -->","summary":"","htmlStringContent":"<!-- begin item 25fe740d-8584-4965-8c79-a74400cd7cfc --><!-- begin field 8adcb8d6-be24-42b7-be31-a74400cd7b4c --><ul><li><strong>Do not prescribe azithromycin to people with:</strong><ul><li>Severe hepatic impairment.</li><li>Drugs that prolong the QT interval (for example amiodarone, sotalol, terfenadine, and amisulpride) — macrolides can also prolong the QT interval, which is a risk factor for torsades de pointes arrythmia.</li><li>Electrolyte disturbances such as hypokalaemia — risk of prolongation of the QT interval.</li><li>A history of QT prolongation or ventricular cardiac arrhythmia, including torsades de pointes.</li></ul></li><li><strong>Prescribe azithromycin with caution to people with:</strong><ul><li>Mild-to-moderate hepatic impairment.</li><li>Severe renal impairment — if estimated glomerular filtration rate (eGFR) is less than 10 mL per minute per 1.73 m<sup>2</sup>.</li><li>Myasthenia gravis — macrolides may aggravate weakness symptoms.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/scarlet-fever/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field 8adcb8d6-be24-42b7-be31-a74400cd7b4c --><!-- end item 25fe740d-8584-4965-8c79-a74400cd7cfc -->","subChapters":[]},{"id":"b9c2df4d-e638-56b4-a659-ca4792054483","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field e5b6ffb6-6455-4abc-9744-a74400cd69cc --><h3>Adverse effects</h3><!-- end field e5b6ffb6-6455-4abc-9744-a74400cd69cc -->","summary":"","htmlStringContent":"<!-- begin item 71891888-b332-4f92-a05e-a74400cd6aad --><!-- begin field 00234507-b3ac-479a-ae1e-a74400cd69cc --><p><strong>Possible adverse effects of </strong><strong>azithromycin include:</strong></p><ul><li>Anaphylaxis (rare). See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/angio-oedema-anaphylaxis/\">Angio-oedema and anaphylaxis</a> for more information.</li><li>Nausea, vomiting, abdominal discomfort, and diarrhoea. Note: severe diarrhoea during or after treatment with antibiotics may be a sign of antibiotic-associated colitis (pseudomembranous colitis). See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a> for more information.</li><li>Hepatotoxicity (including cholestatic jaundice), rash, arthralgia, numbness, oedema, and photosensitivity reaction.</li><li>Pancreatitis, QT interval prolongation, arrhythmias, Stevens-Johnson syndrome, and toxic epidermal necrolysis (rare).</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/scarlet-fever/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field 00234507-b3ac-479a-ae1e-a74400cd69cc --><!-- end item 71891888-b332-4f92-a05e-a74400cd6aad -->","subChapters":[]},{"id":"98b34e30-f1c0-5bf4-9b57-e7bc84f40922","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field a6a74979-fcdd-43e6-a269-a74400cd8ee1 --><h3>Drug interactions</h3><!-- end field a6a74979-fcdd-43e6-a269-a74400cd8ee1 -->","summary":"","htmlStringContent":"<!-- begin item 4aa28b93-27c9-47eb-8510-a74400cd9035 --><!-- begin field da0ddae3-06ea-474d-8afe-a74400cd8ee1 --><p><strong>Possible drug interactions with azithromycin include:</strong></p><ul><li>Warfarin — occasionally and unpredictably, the effects of warfarin may be markedly increased by macrolides.<ul><li>Monitor the international normalized ratio (INR), and adjust the warfarin dose accordingly.</li></ul></li><li>Digoxin — azithromycin increases the concentration of digoxin. The manufacturer advises to monitor digoxin concentration.</li><li>Drugs that prolong the QT interval (such as amiodarone, sotalol, terfenadine, and amisulpride) — all macrolides can prolong the QT interval, and concomitant use of drugs that prolong the QT interval is not recommended.<ul><li>Seek advice from a microbiologist regarding a suitable alternative antibiotic if needed.</li></ul></li><li>Drugs that cause hypokalaemia (such as diuretics, corticosteroids, and short-acting beta<sub>2</sub>-agonists) — hypokalaemia is a risk factor for QT prolongation.<ul><li>Seek advice from a microbiologist regarding a suitable alternative antibiotic if needed.</li></ul></li><li>Colchicine —  azithromycin is predicted to increase the exposure to colchicine. The manufacturer advises to adjust the colchicine dose if it is needed.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/scarlet-fever/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field da0ddae3-06ea-474d-8afe-a74400cd8ee1 --><!-- end item 4aa28b93-27c9-47eb-8510-a74400cd9035 -->","subChapters":[]},{"id":"750021da-4312-551b-b543-586c000d9b84","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field b3ee3e13-76d7-4957-b943-a74400cda5c1 --><h3>Pregnancy and breastfeeding</h3><!-- end field b3ee3e13-76d7-4957-b943-a74400cda5c1 -->","summary":"","htmlStringContent":"<!-- begin item 28db26b2-a3fb-458c-abe8-a74400cda6cc --><!-- begin field 7a9e3bbe-9264-40c6-becc-a74400cda5c1 --><h4>Pregnancy</h4><ul><li>The British National Formulary (BNF) advises that azithromycin should be used in pregnancy only if adequate alternatives are not available [<a class=\"bibliography-reference internal-reference\" href=\"/topics/scarlet-fever/references/\">Joint Formulary Committee, 2020</a>]. </li><li>The UK Teratology Information Service (UKTIS) states that for macrolides as a class, the data do not suggest an increased overall risk of congenital malformation or of cardiac malformations specifically. There are fewer data for azithromycin, and although those which are available do not suggest an increased risk of congenital malformation, one cannot be excluded [<a class=\"bibliography-reference internal-reference\" href=\"/topics/scarlet-fever/references/\">UKTIS, 2019</a>].</li></ul><h4>Breastfeeding</h4><ul><li>The British National Formulary (BNF) states that azithromycin is present in breast milk, and it should only be used if there are no suitable alternatives [<a class=\"bibliography-reference internal-reference\" href=\"/topics/scarlet-fever/references/\">Joint Formulary Committee, 2020</a>].</li></ul><!-- end field 7a9e3bbe-9264-40c6-becc-a74400cda5c1 --><!-- end item 28db26b2-a3fb-458c-abe8-a74400cda6cc -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}